Jaguar Health to Present Initial Results from the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Jaguar Health (NASDAQ:JAGX) has announced an upcoming investor webcast on April 30, 2025, to present initial results from a proof-of-concept study of crofelemer, their plant-based anti-secretory prescription drug. The study focuses on treating Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF).
The preliminary results were presented by Dr. Mohamad Miqdady at the 11th Annual ELITE PED-GI Congress in Abu Dhabi. The webcast will feature key opinion leaders including Dr. Miqdady, Dr. Christos Tzivinikos, and Dr. Pravin Chaturvedi.
Jaguar is currently conducting multiple studies: three proof-of-concept investigator-initiated trials and two placebo-controlled Phase 2 studies across the United States, European Union, and Middle East/North Africa regions. Additional proof-of-concept results are expected throughout 2025, potentially supporting early patient access to crofelemer in EU countries.
Jaguar Health (NASDAQ:JAGX) ha annunciato un webcast per investitori in programma il 30 aprile 2025, durante il quale presenterà i risultati preliminari di uno studio proof-of-concept su crofelemer, il loro farmaco anti-secretorio a base vegetale. Lo studio si concentra sul trattamento della Malattia da Inclusione dei Microvilli (MVID) e della Sindrome dell'Intestino Corto con Insufficienza Intestinale (SBS-IF).
I risultati preliminari sono stati presentati dal dott. Mohamad Miqdady all'11° Congresso Annuale ELITE PED-GI ad Abu Dhabi. Il webcast vedrà la partecipazione di esperti di rilievo, tra cui il dott. Miqdady, il dott. Christos Tzivinikos e il dott. Pravin Chaturvedi.
Jaguar sta attualmente conducendo diversi studi: tre trial proof-of-concept avviati da investigatori e due studi di Fase 2 controllati con placebo negli Stati Uniti, nell'Unione Europea e nelle regioni Medio Oriente/Nord Africa. Ulteriori risultati proof-of-concept sono attesi durante il 2025, con la possibilità di supportare un accesso anticipato al crofelemer nei paesi UE.
Jaguar Health (NASDAQ:JAGX) ha anunciado una próxima transmisión para inversores el 30 de abril de 2025, donde presentará resultados iniciales de un estudio proof-of-concept sobre crofelemer, su medicamento anti-secretor de origen vegetal. El estudio se centra en el tratamiento de la Enfermedad por Inclusión de Microvellosidades (MVID) y el Síndrome de Intestino Corto con Insuficiencia Intestinal (SBS-IF).
Los resultados preliminares fueron presentados por el Dr. Mohamad Miqdady en el 11º Congreso Anual ELITE PED-GI en Abu Dabi. La transmisión contará con líderes de opinión clave, incluyendo al Dr. Miqdady, Dr. Christos Tzivinikos y Dr. Pravin Chaturvedi.
Jaguar está llevando a cabo múltiples estudios: tres ensayos proof-of-concept iniciados por investigadores y dos estudios de Fase 2 controlados con placebo en Estados Unidos, Unión Europea y regiones de Medio Oriente/Norte de África. Se esperan más resultados proof-of-concept durante 2025, que podrían apoyar el acceso temprano de pacientes a crofelemer en países de la UE.
Jaguar Health (NASDAQ:JAGX)는 2025년 4월 30일 예정된 투자자 웹캐스트를 통해 식물성 항분비 처방약인 크로펠레머(crofelemer)의 개념 증명 연구 초기 결과를 발표할 예정입니다. 이 연구는 미세융모 포함 질환(MVID)과 장기능부전 동반 단장증후군(SBS-IF) 치료에 중점을 두고 있습니다.
예비 결과는 아부다비에서 열린 제11회 ELITE PED-GI 연례 학술대회에서 모하마드 미크다디 박사가 발표했습니다. 이번 웹캐스트에는 미크다디 박사, 크리스토스 치비니코스 박사, 프라빈 차투르베디 박사 등 주요 의견 리더들이 참여할 예정입니다.
Jaguar는 현재 미국, 유럽연합, 중동/북아프리카 지역에서 연구자 주도 개념 증명 임상시험 3건과 위약 대조 2상 임상시험 2건을 진행 중입니다. 2025년 내 추가 개념 증명 결과가 기대되며, 이는 유럽연합 국가에서 크로펠레머의 조기 환자 접근 지원에 기여할 수 있습니다.
Jaguar Health (NASDAQ:JAGX) a annoncé un webinaire pour investisseurs prévu le 30 avril 2025, au cours duquel seront présentés les premiers résultats d'une étude proof-of-concept sur le crofélemer, leur médicament anti-sécrétoire d'origine végétale. L'étude porte sur le traitement de la Maladie par Inclusion des Microvillosités (MVID) et du Syndrome de l'Intestin Court avec Insuffisance Intestinale (SBS-IF).
Les résultats préliminaires ont été présentés par le Dr Mohamad Miqdady lors du 11e Congrès annuel ELITE PED-GI à Abou Dhabi. Le webinaire réunira des leaders d'opinion clés, notamment le Dr Miqdady, le Dr Christos Tzivinikos et le Dr Pravin Chaturvedi.
Jaguar mène actuellement plusieurs études : trois essais proof-of-concept initiés par des chercheurs et deux études de phase 2 contrôlées par placebo aux États-Unis, dans l'Union européenne et dans les régions Moyen-Orient/Afrique du Nord. D'autres résultats proof-of-concept sont attendus tout au long de l'année 2025, pouvant potentiellement soutenir un accès précoce au crofélemer dans les pays de l'UE.
Jaguar Health (NASDAQ:JAGX) hat eine bevorstehende Investoren-Webcast für den 30. April 2025 angekündigt, in dem erste Ergebnisse einer Proof-of-Concept-Studie zu Crofelemer, ihrem pflanzenbasierten sekretionshemmenden verschreibungspflichtigen Medikament, vorgestellt werden. Die Studie konzentriert sich auf die Behandlung der Microvillus-Inklusionskrankheit (MVID) und des Kurzdarmsyndroms mit intestinalem Versagen (SBS-IF).
Die vorläufigen Ergebnisse wurden von Dr. Mohamad Miqdady auf dem 11. ELITE PED-GI Jahreskongress in Abu Dhabi präsentiert. Die Webcast wird führende Meinungsbildner wie Dr. Miqdady, Dr. Christos Tzivinikos und Dr. Pravin Chaturvedi umfassen.
Jaguar führt derzeit mehrere Studien durch: drei von Forschern initiierte Proof-of-Concept-Studien und zwei placebokontrollierte Phase-2-Studien in den USA, der Europäischen Union sowie den Regionen Naher Osten/Nordafrika. Weitere Proof-of-Concept-Ergebnisse werden im Laufe des Jahres 2025 erwartet, was einen frühen Patientenzugang zu Crofelemer in EU-Ländern unterstützen könnte.
- None.
- None.
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study
SAN FRANCISCO, CA / ACCESS Newswire / April 28, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept (POC) investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates.
The webcast will include commentary from the following KOLs:
Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is Sheikh Khalifa Medical City's (SKMC) Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division, and the primary investigator for the ongoing exploratory, single-arm open label non-randomized trial of crofelemer in Abu Dhabi
Dr. Christos Tzivinikos, Founder of the Pediatric GI Department at Al Jalila Children's Specialty Hospital in Dubai, and an Adjunct Clinical Assistant Professor at Mohammed Bin Rashid University of Medicine and Health Sciences in Dubai
Pravin Chaturvedi, PhD, Chair of Napo's and Jaguar's Scientific Advisory Board (SAB) and Jaguar's Chief Scientific Officer, who chaired a session at the ELITE PED-GI Congress
To learn more about MVID and SBS-IF, click here to view Jaguar's current corporate overview presentation.
Participation Instructions for Jaguar Investor Webcast
When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time
Where: Online
Registration link for conference: Click Here
This study is being conducted at SKMC, a flagship tertiary hospital in the United Arab Emirates and the largest teaching medical center in Abu Dhabi, by Dr. Miqdady, a recognized leader in pediatric gastroenterology who is SKMC's Division Chief of the Pediatric Gastroenterology, Hepatology & Nutrition Division. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi, and serves as a member of Napo's SAB. Dr. Miqdady completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.
Jaguar is currently supporting three POC IITs, and conducting two placebo-controlled Phase 2 studies, for crofelemer for SBS-IF and/or MVID patients in the United States, European Union, and/or Middle East/North Africa regions. The company's Phase 2 study to evaluate the efficacy of crofelemer for MVID in pediatric patients has been initiated, as has the company's Phase 2 study to evaluate the efficacy of crofelemer for SBS-IF in adults. As with the POC IIT of crofelemer in Abu Dhabi in pediatric patients for various CDDs, including SBS-IF or MVID, the independent IIT in the U.S. to evaluate crofelemer for SBS-IF in adults has also begun treating the first patient. The additional IIT is expected to initiate in Q2 2025.
Additional POC results from IITs are expected throughout 2025 and will provide additional preliminary data on the safety and potential effectiveness of crofelemer for these highly unmet clinical needs. In accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions.
The Annual Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders. Napo was a Bronze-level sponsor of the 2025 Annual ELITE PED-GI Congress.
About Crofelemer
Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for indigenous communities.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health/
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company will host an investor webcast on April 30, 2025, Jaguar's expectation that an additional IIT will initiate in Q2 2025, Jaguar's expectation that additional POC results from IITs will be available throughout 2025, Jaguar's expectation that POC results from IITs will provide additional preliminary data on the safety and potential effectiveness of crofelemer for MVID and SBS-IF, and Jaguar's expectation that, in accordance with the guidelines of specific EU countries, published data from clinical investigations in MVID and SBS-IF could support reimbursed early patient access to crofelemer for these debilitating conditions. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
hello@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on ACCESS Newswire
FAQ
What are the key findings from Jaguar Health's crofelemer study for MVID and SBS-IF?
How many clinical trials is JAGX currently conducting for crofelemer?
When will additional results from JAGX's crofelemer trials be available?
What is the potential market impact of crofelemer for MVID treatment?
Where is the primary proof-of-concept study for JAGX's crofelemer being conducted?
